(IBDX) iShares Trust - iShares - Ratings and Ratios
Corporate Bonds, Investment Grade
Description: IBDX iShares Trust - iShares August 21, 2025
The iShares iBonds Dec2032 Term Corporate ETF (IBDX) is a target maturity ETF that provides investors with exposure to a diversified portfolio of corporate bonds maturing in December 2032. As a fixed income investment, its performance is closely tied to interest rates and credit spreads.
Key drivers of the ETFs performance include the overall direction of interest rates, with rising rates typically leading to declining bond prices, and the creditworthiness of the underlying corporate issuers. The ETFs holdings are likely comprised of investment-grade corporate bonds, making it sensitive to changes in credit spreads, which can be influenced by economic conditions and market sentiment.
To evaluate the ETFs potential performance, key metrics to monitor include its yield-to-maturity (YTM), duration, and credit quality. A higher YTM may indicate a more attractive income stream, but also potentially higher credit risk. Duration measures the ETFs sensitivity to interest rate changes, with longer durations indicating greater sensitivity. Credit quality is also crucial, as a higher proportion of lower-rated issuers can increase the risk of default.
The ETFs AUM of $1.189 billion indicates a moderate level of investor interest, which can contribute to liquidity. However, investors should be aware that the ETFs trading volume and liquidity can impact its ability to efficiently enter or exit positions.
Investors in IBDX should also consider the broader economic context, including the outlook for interest rates, inflation, and economic growth, as these factors can significantly impact the ETFs performance. A thorough analysis of these factors, combined with a detailed examination of the ETFs underlying holdings and key metrics, is essential for making informed investment decisions.
IBDX ETF Overview
| Market Cap in USD | 1,335m |
| Category | Target Maturity |
| TER | 0.10% |
| IPO / Inception | 2022-06-28 |
IBDX ETF Ratings
| Growth Rating | 77.1% |
| Fundamental | - |
| Dividend Rating | 68.9% |
| Return 12m vs S&P 500 | -11.2% |
| Analyst Rating | - |
IBDX Dividends
| Dividend Yield 12m | 4.44% |
| Yield on Cost 5y | 5.28% |
| Annual Growth 5y | 46.30% |
| Payout Consistency | 100.0% |
| Payout Ratio | % |
IBDX Growth Ratios
| Growth Correlation 3m | 87.1% |
| Growth Correlation 12m | 93.3% |
| Growth Correlation 5y | 90.3% |
| CAGR 5y | 8.30% |
| CAGR/Max DD 3y (Calmar Ratio) | 1.03 |
| CAGR/Mean DD 3y (Pain Ratio) | 4.66 |
| Sharpe Ratio 12m | 1.05 |
| Alpha | -14.68 |
| Beta | 1.230 |
| Volatility | 3.47% |
| Current Volume | 187.1k |
| Average Volume 20d | 208.6k |
| Stop Loss | 24.8 (-3.1%) |
| Signal | -0.11 |
What is the price of IBDX shares?
Over the past week, the price has changed by -0.89%, over one month by -0.20%, over three months by +1.67% and over the past year by +7.54%.
Is iShares Trust - iShares a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of IBDX is around 25.22 USD . This means that IBDX is currently overvalued and has a potential downside of -1.45%.
Is IBDX a buy, sell or hold?
What are the forecasts/targets for the IBDX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 28.6 | 11.9% |
IBDX Fundamental Data Overview October 20, 2025
Beta = 1.23
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 1.33b USD (1.33b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 1.33b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 1.33b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 10.55% (E(1.33b)/V(1.33b) * Re(10.55%) + (debt-free company))
Discount Rate = 10.55% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for IBDX ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle